PsyMed Ventures is an early-stage venture capital fund investing in frontier brain and mental health technologies, including neurotechnology, precision psychiatry, novel therapeutics, digital therapeutics, and AI-driven approaches. The firm typically invests $500K to $1.5M per portfolio company.
38% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Average disclosed round size is $26.5M (across 6 rounds with reported amounts).
Portfolio
7
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 AERSKA | Seed | $21M | Oct 2025 |
| MMotif Neurotech | Unknown | $18.8M | Jan 2024 |
 Journey Clinical | Series A | — | Jan 2023 |
 Delix Therapeutics | Series A | $70M | Sep 2021 |
| Journey Clinical | Seed | $3M | Sep 2021 |
 FREEDOM BIOSCIENCES | Seed | $10.5M | — |
 Remepy | Series A | $36M | — |
| NNEURODE | Pre-Seed | — | — |
Top Co-Investors
Palo Santo3 shared
Fifty Years2 shared
Dolby Family Ventures2 shared
re.Mind Capital2 shared
Solari Capital1 shared
Union Square Ventures1 shared
Coalition Operators1 shared
Gaingels1 shared
Mosaic Ventures1 shared
AlleyCorp1 shared
SV Angel1 shared
Able Partners1 shared
Norrsken VC1 shared
Speedinvest1 shared
Exor Ventures1 shared
age11 shared
Backed VC1 shared
BlueYard Capital1 shared
Adara Ventures1 shared
OKX Ventures1 shared
Last updated: 8 September 2026